IMMUNOGEN, INC. 830 Winter Street Waltham, MA 02451

May 9, 2017

Via EDGAR

Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549

Attention: Suzanne Hayes, Assistant Director Ada Sarmento

Re: ImmunoGen, Inc. Registration Statement on Form S-3 Filed on March 3, 2017, as amended on May 5, 2017 File No. 333-216438

Ladies and Gentlemen:

Pursuant to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, ImmunoGen, Inc. (the "Company") hereby requests that the effectiveness of the above-captioned Registration Statement on Form S-3 be accelerated to Thursday, May 11, 2017, at 5:00 p.m., EDT, or as soon as thereafter practicable.

Any questions should be addressed to Daniel T. Kajunski, Esq., at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111, telephone (617) 348-1715.

Thank you for your attention to this matter.

Very truly yours,

ImmunoGen, Inc.

/s/ Mark J. Enyedy

Mark J. Enyedy President and Chief Executive Officer

cc: <u>Securities and Exchange Commission</u> Suzanne Hayes, Assistant Director Ada Sarmento

> <u>ImmunoGen, Inc.</u> David B. Johnston Craig Barrows

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Daniel T. Kajunski, Esq.